insmed bronchiectasis

News

FDA, bronchiectasis and Chronic Lung Disease

First drug to treat bronchiectasis lung condition approved by FDA

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri.

BioPharma Dive · 4d

Insmed gains US approval of lung disease drug forecast to be blockbuster

· 4d

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Stocktwits on MSN3d

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

VytlOne Announces New Partnership with Insmed

Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

FDA, bronchiectasis and Chronic Lung Disease

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

VytlOne Announces New Partnership with Insmed

Trending now